

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

COMPLETION OF AMENDMENTS TO THE TERMS AND CONDITIONS OF THE CONVERTIBLE NOTES

Reference is made to the announcement of the Company dated 3 March 2023 (“**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement. The Board is pleased to announce that all conditions precedent to the Proposed Amendments under the Supplemental Deed have been fulfilled and the Proposed Amendments have become effective on 20 March 2023.

The Company would like to clarify that the Amended Conversion Price of HK\$0.098 per Conversion Share represents (i) a premium of approximately 7.70% to the closing price of HK\$0.091 as quoted on the Stock Exchange on the date of the Supplemental Deed and (ii) a premium of approximately 6.99% to the average closing price of HK\$0.0916 as quoted on the Stock Exchange for the last five trading days immediately before the date of the Supplemental Deed.

By Order of the Board of
Sanai Health Industry Group Company Limited
SHE Hao
Executive Director

Hong Kong, 20 March 2023

As at the date of this announcement, the board of directors of the Company comprises five executive directors, namely, Mr. Chen Chengqing, Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.